Paloma Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Paloma Partners’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-32,858	Closed	-$135K	–	2458
2017 Q4	$135K	Buy	+32,858	New	+$143K	﹤0.01%	1775
2017 Q3	–	Sell	-78,350	Closed	-$261K	–	2721
2017 Q2	$261K	Buy	+78,350	New	+$325K	﹤0.01%	1867

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Paloma Partners's OMED Position: Q1 2018 in Review

Paloma Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 32,858 shares — an estimated $135K sold.

Paloma Partners first reported a position in OMED in Q2 2017 and held it in 2 quarters. The position peaked at $261K in Q2 2017. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

Paloma Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Paloma Partners sold 32,858 OncoMed Pharmaceuticals, Inc. shares in Q1 2018, an estimated $135K.
Paloma Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
Paloma Partners's OncoMed Pharmaceuticals, Inc. position peaked at $261K in Q2 2017.
66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on Paloma Partners's 13F filing for Q1 2018, filed 15 May 2018.